JHP Pharmaceuticals, a provider of global contract manufacturing services for sterile products, has entered into a manufacturing agreement with an undisclosed pharmaceutical company which has developed proprietary products that provide sustained and localized drug concentration. The agreement is for technical transfer, registration batch manufacture and commercial supply of a unique late stage ophthalmic product.
JHP's manufacturing expertise and cGMP compliance history were critical factors in the selection process. Stuart Hinchen, President and CEO stated, "This important product has critical manufacturing requirements. We have successfully manufactured and filled a number of different products over the past few years, all with unique parameters. Our experience in this area provides our customers with a sound resource as the product moves through launch and commercialization. Our record of cGMP compliance driven by experienced quality and regulatory teams continues to be one of the key reasons customers chose JHP." Hinchen noted, "JHP is now expanding its manufacturing capabilities by introducing a new ophthalmic filling line that will further enhance production effectiveness. This innovative equipment will offer a disposable filling circuit, reduced line losses and broader product handling capabilities all in a restricted access configuration. At the moment, the new filling line is under construction and is expected to be fully operational during the second half of 2014."